Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.39 |
| ▸ | LCK | P06239 | 6/20 | 0.39 |
| ▸ | KDR | P35968 | 5/20 | 0.39 |
| ▸ | TEK | Q02763 | 5/20 | 0.39 |
| ▸ | RET | P07949 | 7/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.35 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.35 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29588944 | 0.83 | ADK (0.45) | SRCEGFRYTHDC1LCKKDR | |
| SCHEMBL19304151 | 0.77 | LCK (0.47) | SRCEGFRLCKKDRTEK | |
| SCHEMBL19304156 | 0.77 | SRC (0.62) | SRCEGFRLCKKDRTEK | |
| SCHEMBL14725428 | 0.76 | MEN1 (0.32) | — | |
| SCHEMBL13019648 | 0.71 | SRC (0.43) | SRCEGFRYTHDC1LCKKDR | |
| SCHEMBL14725427 | 0.70 | YTHDC1 (0.62) | YTHDC1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22521390 | 0.69 | YTHDC1 (0.40) | SRCEGFRYTHDC1RETLMNA | |
| SCHEMBL13019651 | 0.68 | YTHDC1 (0.46) | SRCEGFRYTHDC1KDRLMNA | |
| SCHEMBL25467969 | 0.67 | SRC (0.44) | SRCEGFRLCKKDRTEK | |
| SCHEMBL19684532 | 0.67 | SRC (0.44) | SRCEGFRLCKKDRTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | BANK OF AMERICA, N.A. | 2017-04-20 | — | — | US | disclosed |
| US-9566340-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20160101189-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | BANK OF AMERICA, N.A. | 2016-04-14 | — | — | US | disclosed |
| US-9198972-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20130053334-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053334-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | DNMT1, FANCI, PCNA | SRC 410/4885EGFR 888/4885YTHDC1 817/4885 |
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | FANCI, PCNA, DNMT1 | SRC 390/4885EGFR 848/4885YTHDC1 1013/4885 |
| US-20160101189-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | FANCI, PCNA, DNMT1 | SRC 390/4885EGFR 848/4885YTHDC1 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.